<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004095</url>
  </required_header>
  <id_info>
    <org_study_id>NU 98X3</org_study_id>
    <secondary_id>NU-98X3</secondary_id>
    <secondary_id>P-UPJOHN-976475157</secondary_id>
    <secondary_id>NCI-G99-1588</secondary_id>
    <nct_id>NCT00004095</nct_id>
  </id_info>
  <brief_title>Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors</brief_title>
  <official_title>Phase I Trial of Irinotecan (CPT-11) and Gemcitabine in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining irinotecan and gemcitabine in&#xD;
      treating patients who have unresectable or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and the principal toxicities of irinotecan&#xD;
           and gemcitabine in patients with surgically unresectable or metastatic solid tumors.&#xD;
&#xD;
        -  Determine if the principal toxicities and MTD of this combination regimen are affected&#xD;
           by drug sequencing in this patient population.&#xD;
&#xD;
        -  Determine the potential for gemcitabine to alter the pharmacokinetic characteristics&#xD;
           when administered with irinotecan in these patients.&#xD;
&#xD;
        -  Describe the influence effected by varying the administration sequence of this&#xD;
           combination regimen in this patient population.&#xD;
&#xD;
        -  Obtain preliminary data regarding efficacy of this combination regimen in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive irinotecan IV over 90 minutes followed by gemcitabine IV over 30 minutes on&#xD;
      days 1 and 15. Treatment repeats every 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity. Once the maximum tolerated dose (MTD) is reached, patients receive&#xD;
      subsequent doses of the inverse sequence of the combination drugs until a new MTD is&#xD;
      determined.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan and gemcitabine until the MTD&#xD;
      is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients&#xD;
      experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed every 3 months until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan Plus Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Irinotecan Plus Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Irinotecan Plus Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic or surgically unresectable solid tumor, having&#xD;
             received the following maximum number of prior therapies for advanced disease:&#xD;
&#xD;
               -  Bladder cancer - no more than 1 prior therapy&#xD;
&#xD;
               -  Breast cancer - no more than 2 prior therapies&#xD;
&#xD;
               -  Colorectal cancer - no more than 1 prior therapy&#xD;
&#xD;
               -  Kidney cancer - no prior therapy&#xD;
&#xD;
               -  Lung cancer - no more than 1 prior therapy&#xD;
&#xD;
               -  Pancreatic cancer - no prior therapy&#xD;
&#xD;
          -  Bidimensionally measurable disease outside a previously irradiated field&#xD;
&#xD;
               -  At least 2 cm x 2 cm&#xD;
&#xD;
          -  No known bone metastases&#xD;
&#xD;
          -  CNS involvement allowed if successfully controlled by surgery or radiotherapy and not&#xD;
             requiring corticosteroids&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL regardless of liver involvement secondary to tumor&#xD;
&#xD;
          -  SGOT no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN&#xD;
             if liver metastases present)&#xD;
&#xD;
          -  No known Gilbert's disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
          -  Calcium less than 12.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure requiring therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active uncontrolled bacterial, viral (including HIV), or invasive fungal infection&#xD;
&#xD;
          -  No psychiatric disorders that would prevent compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior irinotecan, topotecan, or gemcitabine&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed, if at least 1 year between last dose of adjuvant&#xD;
             chemotherapy and recurrence of cancer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to less than 30% of bone marrow&#xD;
&#xD;
          -  No prior whole pelvic radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Al B. Benson, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wisinski KB, Mulcahy MF, Newman S, et al.: A phase I study of irinotecan and gemcitabine in solid tumors. [Abstract] American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium, 19 -21 January 2007, Orlando, Florida A-140, 2007.</citation>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

